1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Follicular Lymphoma Drugs by Type
  • 1.3.1 Overview: Global Follicular Lymphoma Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
  • 1.3.2 Global Follicular Lymphoma Drugs Consumption Value Market Share by Type in 2023
  • 1.3.3 Anti-CD20 mAbs
  • 1.3.4 Chemotherapy Agents
  • 1.3.5 Kinase Inhibitor
  • 1.3.6 Others
• 1.4 Global Follicular Lymphoma Drugs Market by Administration Route
  • 1.4.1 Overview: Global Follicular Lymphoma Drugs Market Size by Administration Route: 2019 Versus 2023 Versus 2030
  • 1.4.2 Injection
  • 1.4.3 Oral
• 1.5 Global Follicular Lymphoma Drugs Market Size & Forecast
• 1.6 Global Follicular Lymphoma Drugs Market Size and Forecast by Region
  • 1.6.1 Global Follicular Lymphoma Drugs Market Size by Region: 2019 VS 2023 VS 2030
  • 1.6.2 Global Follicular Lymphoma Drugs Market Size by Region, (2019-2030)
  • 1.6.3 North America Follicular Lymphoma Drugs Market Size and Prospect (2019-2030)
  • 1.6.4 Europe Follicular Lymphoma Drugs Market Size and Prospect (2019-2030)
  • 1.6.5 Asia-Pacific Follicular Lymphoma Drugs Market Size and Prospect (2019-2030)
  • 1.6.6 South America Follicular Lymphoma Drugs Market Size and Prospect (2019-2030)
  • 1.6.7 Middle East & Africa Follicular Lymphoma Drugs Market Size and Prospect (2019-2030)

2 Company Profiles

• 2.1 Roche
  • 2.1.1 Roche Details
  • 2.1.2 Roche Major Business
  • 2.1.3 Roche Follicular Lymphoma Drugs Product and Solutions
  • 2.1.4 Roche Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.1.5 Roche Recent Developments and Future Plans
• 2.2 Gilead Sciences
  • 2.2.1 Gilead Sciences Details
  • 2.2.2 Gilead Sciences Major Business
  • 2.2.3 Gilead Sciences Follicular Lymphoma Drugs Product and Solutions
  • 2.2.4 Gilead Sciences Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.2.5 Gilead Sciences Recent Developments and Future Plans
• 2.3 TG Therapeutics
  • 2.3.1 TG Therapeutics Details
  • 2.3.2 TG Therapeutics Major Business
  • 2.3.3 TG Therapeutics Follicular Lymphoma Drugs Product and Solutions
  • 2.3.4 TG Therapeutics Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.3.5 TG Therapeutics Recent Developments and Future Plans
• 2.4 Bayer
  • 2.4.1 Bayer Details
  • 2.4.2 Bayer Major Business
  • 2.4.3 Bayer Follicular Lymphoma Drugs Product and Solutions
  • 2.4.4 Bayer Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.4.5 Bayer Recent Developments and Future Plans
• 2.5 Secura Bio
  • 2.5.1 Secura Bio Details
  • 2.5.2 Secura Bio Major Business
  • 2.5.3 Secura Bio Follicular Lymphoma Drugs Product and Solutions
  • 2.5.4 Secura Bio Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.5.5 Secura Bio Recent Developments and Future Plans
• 2.6 Epizyme
  • 2.6.1 Epizyme Details
  • 2.6.2 Epizyme Major Business
  • 2.6.3 Epizyme Follicular Lymphoma Drugs Product and Solutions
  • 2.6.4 Epizyme Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.6.5 Epizyme Recent Developments and Future Plans
• 2.7 Eisai
  • 2.7.1 Eisai Details
  • 2.7.2 Eisai Major Business
  • 2.7.3 Eisai Follicular Lymphoma Drugs Product and Solutions
  • 2.7.4 Eisai Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.7.5 Eisai Recent Developments and Future Plans
• 2.8 Acrotech Biopharma
  • 2.8.1 Acrotech Biopharma Details
  • 2.8.2 Acrotech Biopharma Major Business
  • 2.8.3 Acrotech Biopharma Follicular Lymphoma Drugs Product and Solutions
  • 2.8.4 Acrotech Biopharma Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.8.5 Acrotech Biopharma Recent Developments and Future Plans
• 2.9 Teva
  • 2.9.1 Teva Details
  • 2.9.2 Teva Major Business
  • 2.9.3 Teva Follicular Lymphoma Drugs Product and Solutions
  • 2.9.4 Teva Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.9.5 Teva Recent Developments and Future Plans
• 2.10 Eagle Pharmaceuticals
  • 2.10.1 Eagle Pharmaceuticals Details
  • 2.10.2 Eagle Pharmaceuticals Major Business
  • 2.10.3 Eagle Pharmaceuticals Follicular Lymphoma Drugs Product and Solutions
  • 2.10.4 Eagle Pharmaceuticals Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.10.5 Eagle Pharmaceuticals Recent Developments and Future Plans
• 2.11 MundiPharma
  • 2.11.1 MundiPharma Details
  • 2.11.2 MundiPharma Major Business
  • 2.11.3 MundiPharma Follicular Lymphoma Drugs Product and Solutions
  • 2.11.4 MundiPharma Follicular Lymphoma Drugs Revenue, Gross Margin and Market Share (2019-2024)
  • 2.11.5 MundiPharma Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Follicular Lymphoma Drugs Revenue and Share by Players (2019-2024)
• 3.2 Market Share Analysis (2023)
  • 3.2.1 Market Share of Follicular Lymphoma Drugs by Company Revenue
  • 3.2.2 Top 3 Follicular Lymphoma Drugs Players Market Share in 2023
  • 3.2.3 Top 6 Follicular Lymphoma Drugs Players Market Share in 2023
• 3.3 Follicular Lymphoma Drugs Market: Overall Company Footprint Analysis
  • 3.3.1 Follicular Lymphoma Drugs Market: Region Footprint
  • 3.3.2 Follicular Lymphoma Drugs Market: Company Product Type Footprint
  • 3.3.3 Follicular Lymphoma Drugs Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Follicular Lymphoma Drugs Consumption Value and Market Share by Type (2019-2024)
• 4.2 Global Follicular Lymphoma Drugs Market Forecast by Type (2025-2030)

5 Market Size Segment by Administration Route

• 5.1 Global Follicular Lymphoma Drugs Consumption Value Market Share by Administration Route (2019-2024)
• 5.2 Global Follicular Lymphoma Drugs Market Forecast by Administration Route (2025-2030)

6 North America

• 6.1 North America Follicular Lymphoma Drugs Consumption Value by Type (2019-2030)
• 6.2 North America Follicular Lymphoma Drugs Market Size by Administration Route (2019-2030)
• 6.3 North America Follicular Lymphoma Drugs Market Size by Country
  • 6.3.1 North America Follicular Lymphoma Drugs Consumption Value by Country (2019-2030)
  • 6.3.2 United States Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 6.3.3 Canada Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 6.3.4 Mexico Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)

7 Europe

• 7.1 Europe Follicular Lymphoma Drugs Consumption Value by Type (2019-2030)
• 7.2 Europe Follicular Lymphoma Drugs Consumption Value by Administration Route (2019-2030)
• 7.3 Europe Follicular Lymphoma Drugs Market Size by Country
  • 7.3.1 Europe Follicular Lymphoma Drugs Consumption Value by Country (2019-2030)
  • 7.3.2 Germany Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 7.3.3 France Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 7.3.4 United Kingdom Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 7.3.5 Russia Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 7.3.6 Italy Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)

8 Asia-Pacific

• 8.1 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Type (2019-2030)
• 8.2 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Administration Route (2019-2030)
• 8.3 Asia-Pacific Follicular Lymphoma Drugs Market Size by Region
  • 8.3.1 Asia-Pacific Follicular Lymphoma Drugs Consumption Value by Region (2019-2030)
  • 8.3.2 China Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 8.3.3 Japan Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 8.3.4 South Korea Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 8.3.5 India Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 8.3.6 Southeast Asia Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 8.3.7 Australia Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)

9 South America

• 9.1 South America Follicular Lymphoma Drugs Consumption Value by Type (2019-2030)
• 9.2 South America Follicular Lymphoma Drugs Consumption Value by Administration Route (2019-2030)
• 9.3 South America Follicular Lymphoma Drugs Market Size by Country
  • 9.3.1 South America Follicular Lymphoma Drugs Consumption Value by Country (2019-2030)
  • 9.3.2 Brazil Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 9.3.3 Argentina Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)

10 Middle East & Africa

• 10.1 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Type (2019-2030)
• 10.2 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Administration Route (2019-2030)
• 10.3 Middle East & Africa Follicular Lymphoma Drugs Market Size by Country
  • 10.3.1 Middle East & Africa Follicular Lymphoma Drugs Consumption Value by Country (2019-2030)
  • 10.3.2 Turkey Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 10.3.3 Saudi Arabia Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)
  • 10.3.4 UAE Follicular Lymphoma Drugs Market Size and Forecast (2019-2030)

11 Market Dynamics

• 11.1 Follicular Lymphoma Drugs Market Drivers
• 11.2 Follicular Lymphoma Drugs Market Restraints
• 11.3 Follicular Lymphoma Drugs Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

• 12.1 Follicular Lymphoma Drugs Industry Chain
• 12.2 Follicular Lymphoma Drugs Upstream Analysis
• 12.3 Follicular Lymphoma Drugs Midstream Analysis
• 12.4 Follicular Lymphoma Drugs Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source

Follicular lymphoma is a cancer that affects white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin"s and non-Hodgkin"s, based on the kind of white blood cell they affect. Follicular lymphoma is a non-Hodgkin"s lymphoma.Drugs for Follicular lymphoma are Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, etc.
According to our (Global Info Research) latest study, the global Follicular Lymphoma Drugs market size was valued at US$ 1902 million in 2023 and is forecast to a readjusted size of USD 3083 million by 2030 with a CAGR of 7.2% during review period.
Global core follicular lymphoma drugs players include Roche, Teva and Bayer etc. The Top3 companies hold a share about 57%. North America is the largest market, with a share about 58%, followed by Europe and Asia Pacific with the share about 21% and 20%.
This report is a detailed and comprehensive analysis for global Follicular Lymphoma Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Administration Route. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Follicular Lymphoma Drugs market size and forecasts, in consumption value ($ Million), 2019-2030
Global Follicular Lymphoma Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Follicular Lymphoma Drugs market size and forecasts, by Type and by Administration Route, in consumption value ($ Million), 2019-2030
Global Follicular Lymphoma Drugs market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Follicular Lymphoma Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Follicular Lymphoma Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Gilead Sciences, TG Therapeutics, Bayer, Secura Bio, Epizyme, Eisai, Acrotech Biopharma, Teva, Eagle Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Follicular Lymphoma Drugs market is split by Type and by Administration Route. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Administration Route. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Follicular Lymphoma Drugs market is split by Type and by Administration Route. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Administration Route. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Anti-CD20 mAbs
Chemotherapy Agents
Kinase Inhibitor
Others
Market segment by Administration Route
Injection
Oral
Market segment by players, this report covers
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Follicular Lymphoma Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Follicular Lymphoma Drugs, with revenue, gross margin, and global market share of Follicular Lymphoma Drugs from 2019 to 2024.
Chapter 3, the Follicular Lymphoma Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Administration Route, with consumption value and growth rate by Type, by Administration Route, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Follicular Lymphoma Drugs market forecast, by regions, by Type and by Administration Route, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Follicular Lymphoma Drugs.
Chapter 13, to describe Follicular Lymphoma Drugs research findings and conclusion.